Humanization with CD34-positive hematopoietic stem cells in NOG-EXL mice results in improved long-term survival and less severe myeloid cell hyperactivation phenotype relative to NSG-SGM3 mice

NSG-SGM3 and NOG-EXL mice combine severe immunodeficiency with transgenic expression of human myeloid stimulatory cytokines, resulting in marked expansion of myeloid populations upon humanization with CD34+ hematopoietic stem cells (HSCs). Humanized NSG-SGM3 mice typically develop a lethal macrophag...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Veterinary pathology Ročník 61; číslo 4; s. 664
Hlavní autori:	Willis, Elinor, Verrelle, Jillian, Banerjee, Esha, Assenmacher, Charles-Antoine, Tarrant, James C, Skuli, Nicholas, Jacobson, Moriah L, O'Rouke, Donald M, Binder, Zev A, Radaelli, Enrico
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.07.2024
Predmet:	Animals Antigens, CD34 - metabolism Disease Models, Animal Hematopoietic Stem Cell Transplantation Hematopoietic Stem Cells - pathology Humans Mice Mice, Transgenic Myeloid Cells - pathology Phenotype NOG-EXL mouse humanization macrophage activation syndrome hemophagocytic lymphohistiocytosis mast cell hyperplasia NSG-SGM3 human hematopoietic stem cells
ISSN:	1544-2217, 1544-2217
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	NSG-SGM3 and NOG-EXL mice combine severe immunodeficiency with transgenic expression of human myeloid stimulatory cytokines, resulting in marked expansion of myeloid populations upon humanization with CD34+ hematopoietic stem cells (HSCs). Humanized NSG-SGM3 mice typically develop a lethal macrophage activation syndrome and mast cell hyperplasia that limit their use in long-term studies (e.g., humanization followed by tumor xenotransplantation). It is currently unclear to what extent humanized NOG-EXL mice suffer from the same condition observed in humanized NSG-SGM3 mice. We compared the effects of human CD34+ HSC engraftment in these two strains in an orthotopic patient-derived glioblastoma model. NSG-SGM3 mice humanized in-house were compared to NOG-EXL mice humanized in-house and commercially available humanized NOG-EXL mice. Mice were euthanized at humane or study endpoints, and complete pathological assessments were performed. A semiquantitative multiparametric clinicopathological scoring system was developed to characterize chimeric myeloid cell hyperactivation (MCH) syndrome. NSG-SGM3 mice were euthanized at 16 weeks after humanization because of severe deterioration of clinical conditions. Humanized NOG-EXL mice survived to the study endpoint at 22 weeks after humanization and showed less-severe MCH phenotypes than NSG-SGM3 mice. Major differences included the lack of mast cell expansion and limited tissue/organ involvement in NOG-EXL mice compared to NSG-SGM3 mice. Engraftment of human lymphocytes, assessed by immunohistochemistry, was similar in the two strains. The longer survival and decreased MCH phenotype severity in NOG-EXL mice enabled their use in a tumor xenotransplantation study. The NOG-EXL model is better suited than the NSG-SGM3 model for immuno-oncology studies requiring long-term survival after humanization.
AbstractList	NSG-SGM3 and NOG-EXL mice combine severe immunodeficiency with transgenic expression of human myeloid stimulatory cytokines, resulting in marked expansion of myeloid populations upon humanization with CD34+ hematopoietic stem cells (HSCs). Humanized NSG-SGM3 mice typically develop a lethal macrophage activation syndrome and mast cell hyperplasia that limit their use in long-term studies (e.g., humanization followed by tumor xenotransplantation). It is currently unclear to what extent humanized NOG-EXL mice suffer from the same condition observed in humanized NSG-SGM3 mice. We compared the effects of human CD34+ HSC engraftment in these two strains in an orthotopic patient-derived glioblastoma model. NSG-SGM3 mice humanized in-house were compared to NOG-EXL mice humanized in-house and commercially available humanized NOG-EXL mice. Mice were euthanized at humane or study endpoints, and complete pathological assessments were performed. A semiquantitative multiparametric clinicopathological scoring system was developed to characterize chimeric myeloid cell hyperactivation (MCH) syndrome. NSG-SGM3 mice were euthanized at 16 weeks after humanization because of severe deterioration of clinical conditions. Humanized NOG-EXL mice survived to the study endpoint at 22 weeks after humanization and showed less-severe MCH phenotypes than NSG-SGM3 mice. Major differences included the lack of mast cell expansion and limited tissue/organ involvement in NOG-EXL mice compared to NSG-SGM3 mice. Engraftment of human lymphocytes, assessed by immunohistochemistry, was similar in the two strains. The longer survival and decreased MCH phenotype severity in NOG-EXL mice enabled their use in a tumor xenotransplantation study. The NOG-EXL model is better suited than the NSG-SGM3 model for immuno-oncology studies requiring long-term survival after humanization. NSG-SGM3 and NOG-EXL mice combine severe immunodeficiency with transgenic expression of human myeloid stimulatory cytokines, resulting in marked expansion of myeloid populations upon humanization with CD34+ hematopoietic stem cells (HSCs). Humanized NSG-SGM3 mice typically develop a lethal macrophage activation syndrome and mast cell hyperplasia that limit their use in long-term studies (e.g., humanization followed by tumor xenotransplantation). It is currently unclear to what extent humanized NOG-EXL mice suffer from the same condition observed in humanized NSG-SGM3 mice. We compared the effects of human CD34+ HSC engraftment in these two strains in an orthotopic patient-derived glioblastoma model. NSG-SGM3 mice humanized in-house were compared to NOG-EXL mice humanized in-house and commercially available humanized NOG-EXL mice. Mice were euthanized at humane or study endpoints, and complete pathological assessments were performed. A semiquantitative multiparametric clinicopathological scoring system was developed to characterize chimeric myeloid cell hyperactivation (MCH) syndrome. NSG-SGM3 mice were euthanized at 16 weeks after humanization because of severe deterioration of clinical conditions. Humanized NOG-EXL mice survived to the study endpoint at 22 weeks after humanization and showed less-severe MCH phenotypes than NSG-SGM3 mice. Major differences included the lack of mast cell expansion and limited tissue/organ involvement in NOG-EXL mice compared to NSG-SGM3 mice. Engraftment of human lymphocytes, assessed by immunohistochemistry, was similar in the two strains. The longer survival and decreased MCH phenotype severity in NOG-EXL mice enabled their use in a tumor xenotransplantation study. The NOG-EXL model is better suited than the NSG-SGM3 model for immuno-oncology studies requiring long-term survival after humanization.NSG-SGM3 and NOG-EXL mice combine severe immunodeficiency with transgenic expression of human myeloid stimulatory cytokines, resulting in marked expansion of myeloid populations upon humanization with CD34+ hematopoietic stem cells (HSCs). Humanized NSG-SGM3 mice typically develop a lethal macrophage activation syndrome and mast cell hyperplasia that limit their use in long-term studies (e.g., humanization followed by tumor xenotransplantation). It is currently unclear to what extent humanized NOG-EXL mice suffer from the same condition observed in humanized NSG-SGM3 mice. We compared the effects of human CD34+ HSC engraftment in these two strains in an orthotopic patient-derived glioblastoma model. NSG-SGM3 mice humanized in-house were compared to NOG-EXL mice humanized in-house and commercially available humanized NOG-EXL mice. Mice were euthanized at humane or study endpoints, and complete pathological assessments were performed. A semiquantitative multiparametric clinicopathological scoring system was developed to characterize chimeric myeloid cell hyperactivation (MCH) syndrome. NSG-SGM3 mice were euthanized at 16 weeks after humanization because of severe deterioration of clinical conditions. Humanized NOG-EXL mice survived to the study endpoint at 22 weeks after humanization and showed less-severe MCH phenotypes than NSG-SGM3 mice. Major differences included the lack of mast cell expansion and limited tissue/organ involvement in NOG-EXL mice compared to NSG-SGM3 mice. Engraftment of human lymphocytes, assessed by immunohistochemistry, was similar in the two strains. The longer survival and decreased MCH phenotype severity in NOG-EXL mice enabled their use in a tumor xenotransplantation study. The NOG-EXL model is better suited than the NSG-SGM3 model for immuno-oncology studies requiring long-term survival after humanization.
Author	Radaelli, Enrico Verrelle, Jillian Skuli, Nicholas O'Rouke, Donald M Tarrant, James C Willis, Elinor Banerjee, Esha Assenmacher, Charles-Antoine Binder, Zev A Jacobson, Moriah L
Author_xml	– sequence: 1 givenname: Elinor surname: Willis fullname: Willis, Elinor organization: Comparative Pathology Core, Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA – sequence: 2 givenname: Jillian surname: Verrelle fullname: Verrelle, Jillian organization: Comparative Pathology Core, Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA – sequence: 3 givenname: Esha surname: Banerjee fullname: Banerjee, Esha organization: Comparative Pathology Core, Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA – sequence: 4 givenname: Charles-Antoine orcidid: 0000-0003-0073-2730 surname: Assenmacher fullname: Assenmacher, Charles-Antoine organization: Comparative Pathology Core, Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA – sequence: 5 givenname: James C surname: Tarrant fullname: Tarrant, James C organization: GlaxoSmithKline, Collegeville, PA – sequence: 6 givenname: Nicholas surname: Skuli fullname: Skuli, Nicholas organization: Stem Cell and Xenograft Core, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA – sequence: 7 givenname: Moriah L surname: Jacobson fullname: Jacobson, Moriah L organization: Taconic Biosciences, Inc., Rensselaer, NY – sequence: 8 givenname: Donald M surname: O'Rouke fullname: O'Rouke, Donald M organization: Department of Neurosurgery, Perelman School of Medicine, GBM Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA – sequence: 9 givenname: Zev A surname: Binder fullname: Binder, Zev A organization: Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA – sequence: 10 givenname: Enrico orcidid: 0000-0002-2885-0221 surname: Radaelli fullname: Radaelli, Enrico organization: Comparative Pathology Core, Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/38197423$$D View this record in MEDLINE/PubMed
BookMark	eNpNUE1PGzEUtCpQQ6A_oBfkI5el_tp4fawCTSoFOJADt8jrfdsYre3t2rtV-uv603ADSLzLexqNZubNHJ344AGhr5RcUyrlN8IJUVVZMU5ZHrr4hM5oKUSRb3ny4Z6heYzPhDCmKvkZzXhFlRSMn6F_69Fpb__qZIPHf2za4-UNF0Ufok12ArwHp1Pog4VkDY4JHDbQdRFbj-8fVsXt0wY7awAPEMcuHXHr-iFM0OAu-F9FgsHhOA6TnXSHtc8wxIgjTDAAdgfogm2Oonh_6GHQJhu_5un34EPKYFbv9DFPCvj-cVU8ru740fcCnba6i_DlbZ-j7Y_b7XJdbB5WP5ffN4URkqWCc1M2ZcVr0TKptFCVMG1JmVooUVMBTc1UzYhZlKBZrYWgpWxZQ4RsjagMO0dXr7L5s98jxLRzNv7PrD2EMe6YopxUuWqRqZdv1LF20Oz6wTo9HHbvpbMXiySI-A
CitedBy_id	crossref_primary_10_1038_s41419_025_07861_0 crossref_primary_10_1177_03009858241279141 crossref_primary_10_3390_life15071129 crossref_primary_10_1177_03009858251372565 crossref_primary_10_3389_fimmu_2025_1624724
ContentType	Journal Article
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1177/03009858231222216
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Veterinary Medicine
EISSN	1544-2217
ExternalDocumentID	38197423
Genre	Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural
GrantInformation_xml	– fundername: NCI NIH HHS grantid: P30 CA016520 – fundername: NIH HHS grantid: S10 OD023465
GroupedDBID	--- -TM ..I .2E .2J .2N .GJ 01A 0R~ 123 1~K 2WC 31R 31U 31X 31Z 4.4 53G 54M 5RE 5VS AABMB AACKU AACMV AACTG AADUE AAEWN AAGGD AAGMC AAHBH AAJIQ AAJOX AAKGS AANSI AAPEO AAQXH AAQXI AARDL AARIX AATAA AATBZ AAUAS AAXOT AAYTG AAZBJ ABAWP ABCCA ABCJG ABDWY ABEIX ABFWQ ABHKI ABJIS ABJNI ABKRH ABLUO ABPGX ABPNF ABQKF ABQXT ABRHV ABUJY ABVFX ABVVC ABYTW ACARO ACDSZ ACDXX ACFEJ ACFMA ACFYK ACGBL ACGFO ACGFS ACGZU ACJER ACJTF ACLFY ACLHI ACLZU ACOFE ACOXC ACROE ACSIQ ACUAV ACUIR ACXKE ACXMB ADBBV ADDLC ADEIA ADMPF ADNBR ADNON ADRRZ ADTBJ ADUKL ADVBO ADZZY AECGH AECVZ AEDTQ AEKYL AENEX AEPTA AEQLS AERKM AESZF AEUHG AEWDL AEWHI AEXFG AEXNY AFEET AFFNX AFKBI AFKRG AFMOU AFQAA AFUIA AGHKR AGKLV AGNHF AGPXR AGWFA AHDMH AHJOV AIGRN AJABX AJEFB AJMMQ AJSCY AJUZI AJXAJ ALKWR ALMA_UNASSIGNED_HOLDINGS ALTZF AMCVQ ANDLU ARTOV AUTPY AUVAJ AYAKG B3H B8M B8R B8Z B94 BAWUL BBRGL BDDNI BKIIM BKSCU BPACV BSEHC BWJAD C1A CAG CBRKF CDWPY CFDXU CGR COF CORYS CQQTX CS3 CUTAK CUY CVF DB0 DC- DC. DC0 DD- DD0 DE- DE. DF0 DIK DN0 DO- DOPDO DU5 DV7 E3Z EBS ECGQY ECM EIF EJD EYRJQ F5P FHBDP GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION H13 HF~ HZ~ J8X K.F M4V MW2 N9A NPM NQS O9- P.9 P.B P2P Q1R Q7L Q7U Q83 RKO ROL S01 SAUOL SCNPE SFC SHG SPQ SPV TR2 TVP W8F WOQ ZGI ZONMY ZPPRI ZRKOI ZSSAH ZXP ~KM 7X8 AAPII ABIDT ABJZC ADEBD AJGYC AJHME AJVBE SASJQ
ID	FETCH-LOGICAL-c472t-33c5d583b4f279a4984cf5129694b14edb29b20c65ea2ba44157f2d047fc48c2
IEDL.DBID	7X8
ISICitedReferencesCount	7
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001139679300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1544-2217
IngestDate	Sun Sep 28 12:17:30 EDT 2025 Sat Mar 29 01:29:22 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	4
Keywords	NOG-EXL mouse humanization macrophage activation syndrome hemophagocytic lymphohistiocytosis mast cell hyperplasia NSG-SGM3 human hematopoietic stem cells
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c472t-33c5d583b4f279a4984cf5129694b14edb29b20c65ea2ba44157f2d047fc48c2
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ORCID	0000-0002-2885-0221 0000-0003-0073-2730
OpenAccessLink	https://pubmed.ncbi.nlm.nih.gov/PMC11264550
PMID	38197423
PQID	2913082174
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_2913082174 pubmed_primary_38197423
PublicationCentury	2000
PublicationDate	2024-07-01
PublicationDateYYYYMMDD	2024-07-01
PublicationDate_xml	– month: 07 year: 2024 text: 2024-07-01 day: 01
PublicationDecade	2020
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Veterinary pathology
PublicationTitleAlternate	Vet Pathol
PublicationYear	2024
SSID	ssj0022987
Score	2.4360802
Snippet	NSG-SGM3 and NOG-EXL mice combine severe immunodeficiency with transgenic expression of human myeloid stimulatory cytokines, resulting in marked expansion of...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	664
SubjectTerms	Animals Antigens, CD34 - metabolism Disease Models, Animal Hematopoietic Stem Cell Transplantation Hematopoietic Stem Cells - pathology Humans Mice Mice, Transgenic Myeloid Cells - pathology Phenotype
Title	Humanization with CD34-positive hematopoietic stem cells in NOG-EXL mice results in improved long-term survival and less severe myeloid cell hyperactivation phenotype relative to NSG-SGM3 mice
URI	https://www.ncbi.nlm.nih.gov/pubmed/38197423 https://www.proquest.com/docview/2913082174
Volume	61
WOSCitedRecordID	wos001139679300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LbxMxELaAcuBSILxaHppKvVoktjdenypU2nBIlkqNotyitdemK4V1yCaV-u_4acx4t3BCQuKyB0v2emXvPL6Z-YaxU23N0GvluUZbgSudeV4GrXkgrihUEXme2PkXU10U-XJprnrAre3TKu9lYhLUVXSEkX8UZkTMKmhAn21-cOoaRdHVvoXGQ3Yg0ZShlC69_B1FEMKkBnlEOMMFTu2jmolwSRKTZkZBMNSQYjT-u4WZNM3l0__d4zN22NuY8Km7FM_ZA98M2GBBiS-p-hZmfUD9BfuZQPy-FhMIlIXzz1LxLpfr1kPidI2bWFOxIxDrMxDW30LdQPF1wi-WU6CO9oBu-369S-N1Aip8BevYfOMk-6Hdo0jCSw1lg8MoXQE1st96-H7n17Gu0qJwg05xqtrqcGKg_LNIIDF0JTe4n12E4nrCryczmd77ks0vL-bnX3jf1IE7pcWOS-myKsulVUFoUyqTKxfI6hgbZUfKV1YYK4ZunPlS2JLcPR1ENVQ6OJU78Yo9amLj3zAY-ZBVVhE_Papi62wejFSB2GaCz2U4Yif3p7TCf4a-o2x83LerP-d0xF53R73adOQeK_JgKXp9_A-z37InAm2cLnv3HTsIKDH8e_bY3e7qdvshXUZ8FlezXx5365o
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Humanization+with+CD34-positive+hematopoietic+stem+cells+in+NOG-EXL+mice+results+in+improved+long-term+survival+and+less+severe+myeloid+cell+hyperactivation+phenotype+relative+to+NSG-SGM3+mice&rft.jtitle=Veterinary+pathology&rft.au=Willis%2C+Elinor&rft.au=Verrelle%2C+Jillian&rft.au=Banerjee%2C+Esha&rft.au=Assenmacher%2C+Charles-Antoine&rft.date=2024-07-01&rft.issn=1544-2217&rft.eissn=1544-2217&rft.volume=61&rft.issue=4&rft.spage=664&rft_id=info:doi/10.1177%2F03009858231222216&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1544-2217&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1544-2217&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1544-2217&client=summon